Literature DB >> 20512448

Serum glucose level at hospital admission correlates with left ventricular systolic dysfunction in nondiabetic, acute coronary patients: the Hellenic Heart Failure Study.

Christina Chrysohoou1, Christos Pitsavos, Panagiotis Aggelopoulos, John Skoumas, Eleftherios Tsiamis, Demosthenes B Panagiotakos, Christodoulos Stefanadis.   

Abstract

The purpose of this work was to evaluate the relation between serum glucose levels at hospital admission and left ventricular systolic function in nondiabetic patients with an acute coronary syndrome (ACS). Of the 1000 ACS patients who were consecutively enrolled during 2007-2008, 583 (63 +/- 13 years, 20% females) nondiabetic patients were studied in this work. Of these, 254 presented left ventricular systolic dysfunction (ejection fraction <40%). Biochemical measurements and detailed medical information were recorded in all participants. Patients having glucose levels at hospital admission in the highest tertile (>155 mg/dl) had lower left ventricular ejection fraction (40% vs 45%, P = 0.003), were older (66 +/- 11 vs 61 +/- 13, P = 0.004) and less physically active (49% vs 63%, P = 0.02), had higher troponin (14.7 +/- 39.7 vs 5.6 +/- 13.5, P = 0.03), higher brain natriuretic peptide (510.39 +/- 932.33 vs 213.4 +/- 301.14, P = 0.008), higher C-RP (42.26 +/- 55.26 vs 26.46 +/- 38.18, P = 0.04), lower creatinine clearance levels (68 +/- 33 vs.81 +/- 31, P = 0.009), higher white blood cell count (13 416 +/- 16 420 vs 9310 +/- 3020, P = 0.001), and lower body mass index (26.8 +/- 4 vs 27.2 +/- 4.4, P = 0.07), compared to those in the lowest tertile (<114 mg/dl). The multiadjusted logistic regression analysis revealed that a 10 mg/dl difference in glucose levels was independently associated with 8% (95% confidence interval 2%-14%) higher likelihood of left ventricular systolic dysfunction. Low glucose concentrations at hospital admission in nondiabetic post-ACS patients is a predictor for the appearance of left ventricular dysfunction, and could be a target marker for risk stratification.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512448     DOI: 10.1007/s00380-009-1192-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  36 in total

1.  Universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Harvey D White
Journal:  Eur Heart J       Date:  2007-10       Impact factor: 29.983

2.  Glucose: a biomarker in acute myocardial infarction ready for prime time?

Authors:  Richard W Nesto; Rodrigo M Lago
Journal:  Circulation       Date:  2008-02-26       Impact factor: 29.690

Review 3.  Glycemia in acute coronary syndromes.

Authors:  M Zeller; B Vergès; I L'Huillier; J M Brun; Y Cottin
Journal:  Diabetes Metab       Date:  2006-09       Impact factor: 6.041

4.  Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study.

Authors:  K Malmberg; A Norhammar; H Wedel; L Rydén
Journal:  Circulation       Date:  1999-05-25       Impact factor: 29.690

5.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).

Authors:  Keith A A Fox; Omar H Dabbous; Robert J Goldberg; Karen S Pieper; Kim A Eagle; Frans Van de Werf; Alvaro Avezum; Shaun G Goodman; Marcus D Flather; Frederick A Anderson; Christopher B Granger
Journal:  BMJ       Date:  2006-10-10

6.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

Authors:  H Kawano; T Motoyama; O Hirashima; N Hirai; Y Miyao; T Sakamoto; K Kugiyama; H Ogawa; H Yasue
Journal:  J Am Coll Cardiol       Date:  1999-07       Impact factor: 24.094

7.  Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy.

Authors:  H V Barron; C P Cannon; S A Murphy; E Braunwald; C M Gibson
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  Chronotropic and neurohumoral markers for the evaluation of functional capacity in patients with impaired left ventricular function.

Authors:  Manolis S Kallistratos; Athanlaslos Dritsas; Ioannis D Laoutaris; Dennis V Cokkinos
Journal:  Hellenic J Cardiol       Date:  2008 Jan-Feb

9.  Insulin resistance and acute coronary syndrome in the young Japanese population have a strong association.

Authors:  Nobutaka Ikeda; Rintaro Nakajima; Taro Tsunoda; Masato Nakamura; Kaoru Sugi
Journal:  Heart Vessels       Date:  2007-05-21       Impact factor: 2.037

10.  Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus.

Authors:  S Lehto; K Pyörälä; H Miettinen; T Rönnemaa; P Palomäki; J Tuomilehto; M Laakso
Journal:  J Intern Med       Date:  1994-09       Impact factor: 8.989

View more
  3 in total

1.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

2.  Inhibition of mini-TyrRS-induced angiogenesis response in endothelial cells by VE-cadherin-dependent mini-TrpRS.

Authors:  Rui Zeng; Yu-cheng Chen; Zhi Zeng; Xiao-xia Liu; Rui Liu; Ou Qiang; Xian Li
Journal:  Heart Vessels       Date:  2011-03-26       Impact factor: 2.037

3.  Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction.

Authors:  Joanna Gierach; Marcin Gierach; Iwona Świątkiewicz; Marek Woźnicki; Grzegorz Grześk; Adam Sukiennik; Marek Koziñski; Jacek Kubica
Journal:  Heart Vessels       Date:  2014-12-25       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.